Multidisciplinary approach for HCC patients: Hepatology for the oncologists

Annals of Oncology

Volumn 24, Issue SUPPL.2, 2013, Pages 15-23

  Barone Prof , C ^a   Koeberle, D ^b   Metselaar, H ^c   Parisi, G ^d   Sansonno, D ^e   Spinzi, G ^f  

^a CATHOLIC UNIVERSITY   (Italy)

^b St Claraspital AG   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Center of Sleep Breathing Medicine   (Italy)

^e UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^f UOC Gastroenterologia H Valduce Como   (Italy)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Multidisciplinary approach

Indexed keywords

ALBUMIN; AMOXICILLIN PLUS CLAVULANIC ACID; ASPARTIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEFOTAXIME; CEFTRIAXONE; FUROSEMIDE; GLUCOSE; MIDODRINE; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; ORNITHINE; PROPRANOLOL; SORAFENIB; SPIRONOLACTONE; TERLIPRESSIN; VASOPRESSIN;

ARTICLE; ASCITES; BACTERIAL PERITONITIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; GENERAL PRACTITIONER; HEPATIC ENCEPHALOPATHY; HEPATOLOGIST; HEPATORENAL SYNDROME; HUMAN; LIGATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; MEDICAL HISTORY; MEDICAL SPECIALIST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; NURSE; ONCOLOGIST; PATHOLOGIST; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOLOGIST; STOMACH VARICES; STOMACH VARICES BLEEDING; SURGEON;

EID: 84878648656     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt053     Document Type: Article

References (49)

1. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56(4): 908-943.
2. Cabibbo G, Rolle E, De Giorgio M et al; HCC Working Group. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Rev Anticancer Ther 2011; 11(12): 1807-1816.
3. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
4. Capocaccia R, Sant M, Berrino F et al. EUROCARE Working Group. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 2007; 102(8): 1661-1670.
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362 (9399): 1907-1917.
6. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
7. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009; 10: 25-34.
8. Verslype C, Van Cutsem E, Dicato M et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 2009; 20 (Suppl 7): vii1-vii6.
9. Lencioni R, Chen XP, Dagher L et al. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 2010; 15 (Suppl 4): 42-52.
10. Gish RG, Lencioni R, Di Bisceglie AM et al. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2012; 6(2): 173-185.
11. Guy J, Kelley RK, Roberts J et al. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2012; 10(4): 354-362.
12. Sherman M, Burak K, Maroun J et al. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011; 18(5): 228-240.
13. Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist 2010; 15(Suppl 4): 23-33.
14. Choi SB, Lee JG, Kim KS et al. The prognosis and survival analysis according to seven staging systems of hepatocellular carcinoma following curative resection. Hepatogastroenterology 2008; 55: 2140-2145.
15. Cillo U, Bassanello M, Vitale A et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 2004; 40: 124-131.
16. Lu W, Dong J, Huang Z et al. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol 2008; 23: 1874-1878.
17. Marrero JA, Fontana RJ, Barrat A et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-716.
18. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
19. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
20. Forner A, Reig ME, de Lope CR et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
21. Bruix J, Sherman M.; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
22. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
23. Chan AC, Poon RT, Ng KK et al. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg. 2008; 247(4): 666-673.
24. Taylor C, Munro AJ, Glynne-Jones R et al. Multidisciplinary team working in cancer: what is the evidence? Br Med J 2010; 340: c951.
25. Chang TT, Sawhney R, Monto A et al. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford) 2008; 10(6): 405-411.
26. Mazzaferro V, Majno P. Principles for the best multidisciplinary meetings. Lancet Oncol 2011; 12(4): 323-325.
27. Donckier V, Van Laethem JL, Van Gansbeke D et al. New considerations for an overall approach to treat hepatocellular carcinoma in cirrhotic patients. J Surg Oncol 2003; 84(1): 36-44.
28. Parisi G. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? Yes. Eur J Intern Med 2012; 23(1): 34-36.
29. Heuman DM, Gilles HS, Solomon C et al Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? No. Eur J Intern Med 2012; 23(1): 37-39.
30. Garcia-Tsao G, Lim JK.; Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affair. Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009; 104(7): 1802-1829.
31. MELD/PELD Calculator Documentation [on-line]. www.unos.org/docs/MELD_PELD_Calculator_Documentation.pdf (19 March 2012, date last accessed).
32. Pagliaro L, D'Amico G, Pasta L et al Portal hypertension in cirrhosis: natural history. In Bosch J, Groszmann RJ (eds). Portal Hypertension. Pathophysiology and Treatment. Oxford, Blackwell Scientific, 1994;72-92.
33. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988; 319: 983-989.
34. Chen W, Nikolova D, Frederiksen SL et al. Beta-blockers reduce mortality in cirrhotic patients with oesophageal varices who have never bled (Cochrane review). J Hepatol 2004; 40 (Suppl 1): 67 [abstract].
35. Khuroo MS, Khuroo NS, Farahat KL et al. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 2005; 21: 347-361.
36. Garcia-Pagan JC, Bosch J. Endoscopic band ligation in the treatment of portal hypertension. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 526-535.
37. Gluud LL, Klingenberg S, Nikolova D et al. Banding ligation versus betablockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol 2007; 102: 2842-2848.
38. Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding - unresolved issues. Summary of an American Association for the Study of Liver Diseases and European Association for the Study of the Liver Single-Topic Conference. Hepatology 2008; 47: 1764-1772.
39. Gines P, Quintero E, Arroyo V. Compensated cirrhosis: natural history and prognosis. Hepatology 1987; 7: 122-128.
40. Fogel MR, Sawhney VK, Neal A et al Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol 1981; 3(Suppl 1): 73-80.
41. Perez-Ayuso RM, Arroyo V, Planas R et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the reninaldosterone system. Gastroenterology 1983; 84: 961-968.
42. Garcia-Tsao G. Spontaneous bacterial peritonitis: a historical perspective. J Hepatol 2004; 41: 522-527.
43. Rimola A, Garcia-Tsao G, Navasa M et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis a consensus document. J Hepatol 2000; 32: 142-153.
44. Acevedo J, Fernandez J, Castro M et al. Current efficacy of recommended empirical antibiotic therapy in patients with cirrhosis and bacterial infection. J Hepatol 2009; 50(Suppl 1) [abstract].
45. Fong TL, Akriviadis EA, Runyon BA et al. Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology 1989; 9: 423-426.
46. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-409.
47. Gines A, Escorsell A, Gines P et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-236.
48. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28: 81-95.
49. Ferenci P, Lockwood A, Mullen KD et al. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-721.